Ho Yin Lo

USPTO Granted Patents = 15 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 101(Granted Patents)

Company Filing History:

10 out of 1,535

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

5. 1 out of 1

Moexa Pharmaceuticals Limited

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12090149 - SMAD3 inhibitors (2024-09-17),

2. 11731985 - Compositions and methods for treating cancer (2023-08-22),

3. 11497747 - Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections (2022-11-15),

4. 11304947 - Compositions and methods for treating lung injuries associated with SARS-COV-2 infections (2022-04-19),

5. 9174980 - Heterocyclic compounds as inhibitors of leukotriene production (2015-11-03),

6. 9150556 - Benzimidazolone chymase inhibitors (2015-10-06),

7. 9062056 - Aza-benzimidazolone Chymase inhibitors (2015-06-23),

8. 8829200 - Benzimidazole inhibitors of leukotriene production (2014-09-09),

9. 8772304 - Benzimidazole inhibitors of leukotriene production (2014-07-08),

10. 8658661 - Oxadiazole inhibitors of leukotriene production (2014-02-25),

11. 8618300 - Indolizine inhibitors of leukotriene production (2013-12-31),

12. 8580829 - Oxadiazole inhibitors of leukotriene production (2013-11-12),

13. 8580825 - Oxadiazole inhibitors of leukotriene production (2013-11-12),

14. 8377949 - Quinazolinedione chymase inhibitors (2013-02-19),

15. 7138420 - Substituted benzimidazole compounds (2006-11-21),

Title: The Innovative Contributions of Ho Yin Lo

Introduction

Ho Yin Lo is a prominent inventor based in Bethel, CT (US), known for his significant contributions to the field of cancer treatment. With a total of 15 patents to his name, he has made remarkable strides in developing compounds that target cancer cell proliferation.

Latest Patents

Among his latest patents are the SMAD3 inhibitors, which include specific compounds of Formula 1 or Formula 2, or their pharmaceutically acceptable salts. These compounds are designed for use in treating or preventing cell proliferation or cancer in subjects. Another notable patent focuses on compositions and methods for treating cancer, particularly a family of benzothiazolyl urea or thiorurea compounds that serve as anti-cancer agents. This invention also encompasses methods for treating various cancers using these innovative compounds.

Career Highlights

Ho Yin Lo has worked with esteemed companies such as Boehringer Ingelheim International GmbH and Qx Therapeutics Inc. His experience in these organizations has allowed him to refine his expertise in the development of therapeutic compounds.

Collaborations

Throughout his career, Ho Yin Lo has collaborated with notable professionals, including Stephane De Lombaert and Peter Allen Nemoto. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Ho Yin Lo's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. His patents and collaborations highlight his dedication to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.